Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: Block by antihypertensives, antiarrhythmics, and their analogs

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 2, 2009, Pages 621-627

  Perez Reyes, Edward ^a   Van Deusen, Amy L ^a   Vitko, Iuliia ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMIODARONE; AMLODIPINE; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; BEPRIDIL; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; DEVAPAMIL; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; EFONIDIPINE; FELODIPINE; ISRADIPINE; MIBEFRADIL; NIFEDIPINE; NITRENDIPINE; PERHEXILINE; PHENYLALKYLAMINE; VERAPAMIL;

ALDOSTERONE RELEASE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCIUM ANTAGONISM; CALCIUM TRANSPORT; DRUG MECHANISM; EMBRYO; HUMAN; HUMAN CELL; KIDNEY BLOOD FLOW; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; CELLS, CULTURED; DIHYDROPYRIDINES; HUMANS; MIBEFRADIL; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; VERAPAMIL;

EID: 59649126705     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.145672     Document Type: Article

References (45)

1. Abernethy DR and Schwartz JB (1999) Drug therapy: calcium-antagonist drugs. N Engl J Med 341:1447-1457.
2. Akaike N, Kostyuk PG, and Osipchuk YV (1989) Dihydropyridine-sensitive low-threshold calcium channels in isolated rat hypothalamic neurones. J Physiol (Lond) 412:181-195.
3. Bean BP (1984) Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc Natl Acad Sci U S A 81:6388-6392.
4. Berjukow S, Döring F, Froschmayr M, Grabner M, Glossmann H, and Hering S (1996) Endogenous calcium channels in human embryonic kidney (HEK293) cells. Br J Pharmacol 118:748-754.
5. 2+ signaling during terminal differentiation (fusion) of human myoblasts. Proc Natl Acad Sci U S A 97:7627-7632.
6. Brown GR, Fraser DG, Castile JA, Gaudreault P, Platt DR, and Friedman PA (1986) Nifedipine serum concentrations following sublingual and oral doses. Int J Clin Pharmacol Ther Toxicol 24:283-286.
7. Chemin J, Monteil A, Briquaire C, Richard S, Perez-Reyes E, Nargeot J, and Lory P (2000) Overexpression of T-type calcium channels in HEK-293 cells increases intracellular calcium without affecting cellular proliferation. FEBS Lett 478:166-172.
8. +. Am J Physiol Renal Physiol 276:F674-F683.
9. Clozel JP, Ertel EA, and Ertel SI (1997) Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens Suppl 15:S17-S25.
10. Cohen CJ, Spires S, and Van Skiver D (1992) Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol 100:703-728.
11. Ertel EA, Campbell KP, Harpold MM, Hofmann F, Mori Y, Perez-Reyes E, Schwartz A, Snutch TP, Tanabe T, Birnbaumer L, Tsien RW, and Catterall WA (2000) Nomenclature of voltage-gated calcium channels. Neuron 25:533-535.
12. Ertel EA and Cohen CJ (1994) Voltage-dependent interactions: the influence and significance of membrane potential on drug-receptor interactions. Drug Dev Res 33:204-213.
13. 2+ channels. Br J Pharmacol 143:1050-1057.
14. Godfraind T, Miller R, and Wibo M (1986) Calcium antagonism and calcium entry blockade. Pharmacol Rev 38:321-416.
15. v3.3: insights into prepulse facilitation. Biophys J 83:229-241.
16. 2+ channel block by dihydropyridines: no modulation by the voltage protocol. Eur J Pharmacol 309:317-321.
17. Hayashi K, Kumagai H, and Saruta T (2003) Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens 16:116-122.
18. 2+ channel subtypes and pharmacology in the kidney. Circ Res 100:342-353.
19. 2+ channels. Jpn J Pharmacol 85:339-350.
20. Hirst GD and Edwards FR (1989) Sympathetic neuroeffector transmission in arteries and arterioles. Physiol Rev 69:546-604.
21. 2+ "window" current that enables the expression of bistability-mediated activities. J Physiol (Lond) 517:805-815.
22. Inotsume N, Iwaoka T, Honda M, Nakano M, Okamoto Y, Naomi S, Tomita K, Teramura T, and Higuchi S (1997) Pharmacokinetics of nicardipine enantiomers in healthy young volunteers. Eur J Clin Pharmacol 52:289-292.
23. Krayenbühl JC, Vozeh S, Kondo-Oestreicher M, and Dayer P (1999) Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol 55:559-565.
24. Lipscombe D, Helton TD, and Xu W (2004) L-type calcium channels: the low down. J Neurophysiol 92:2633-2641.
25. Martin RL, Lee JH, Cribbs LL, Perez-Reyes E, and Hanck DA (2000) Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther 295:302-308.
26. McDonough SI and Bean BP (1998) Mibefradil inhibition of T-type calcium channels in cerebellar Purkinje neurons. Mol Pharmacol 54:1080-1087.
27. v3.2 calcium channels. Mol Pharmacol 61:682-694.
28. v1.2. Circ Res 98:105-110.
29. v1.2 for blood pressure regulation. EMBO J 22:6027-6034.
30. Narahashi T (2000) Neuroreceptors and ion channels as the basis for drug action: past, present, and future. J Pharmacol Exp Ther 294:1-26.
31. Nathan S, Pepine CJ, and Bakris GL (2005) Calcium antagonists: effects on cardiorenal risk in hypertensive patients. Hypertension 46:637-642.
32. 2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens Res 29:493-497.
33. 2+ channel cloned from human heart. Naunyn Schmiedeberg Arch Pharmacol 361:590-599.
34. Perez-Reyes E (2003) Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev 83:117-161.
35. 2+ currents in atrial myocytes. Pflugers Arch 420:410-412.
36. Saito T, Fujii K, Takizawa T, Toyosaki T, Kuwabara Y, Kobayashi S, Ichikawa H, Karaki A, Yamazaki Y, Iwata J, Yamada K, Tomiya H, Takeda K, and Inagaki Y (1996) Effects of the new calcium antagonist efonidipine hydrochloride on resting and exercise hemodynamics in patients with stable effort angina. Arzneimittelforschung 46:861-867.
37. 2+ channels. Cell Physiol Biochem 9:242-269.
38. Tanaka H, Komikado C, Shimada H, Takeda K, Namekata I, Kawanishi T, and Shigenobu K (2004) The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium. J Pharmacol Sci 96:499-501.
39. Triggle DJ (2003) 1,4-Dihydropyridines as calcium channel ligands and privileged structures. Cell Mol Neurobiol 23:293-303.
40. Wei XY, Luchowski EM, Rutledge A, Su CM, and Triggle DJ (1986) Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activatorantagonist pairs in smooth muscle. J Pharmacol Exp Ther 239:144-153.
41. 2+ channels. Circ Res 81:526-532.
42. v3.2 (T-type) channels. Assay Drug Dev Technol 1:637-645.
43. v3 T-type channels using molecular and pharmacologic approaches. Assay Drug Dev Technol 5:191-203.
44. 2+ channel through distinct mechanisms. Mol Pharmacol 69:1684-1691.
45. Zhou LX, Finley DK, Hassell AE, and Holtzman JL (1995) Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers. J Pharmacol Exp Ther 273:121-127.